© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Arvinas, Inc. (ARVN) stock surged +4.11%, trading at $12.16 on NASDAQ, up from the previous close of $11.68. The stock opened at $11.74, fluctuating between $11.70 and $12.29 in the recent session.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
| Employees | 430 |
| Beta | 2.45 |
| Sales or Revenue | $78.50M |
| 5Y Sales Change% | -0.07% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |